Real-World Effectiveness and Safety of Antipsychotics in Individuals at Clinical High-Risk for Psychosis: Study Protocol for a Prospective Observational Study (ShangHai at Risk for Psychosis-Phase 2)
GuiSen Wu,1 RanPiao Gan,1 ZhiXing Li,1 LiHua Xu,1 XiaoChen Tang,1 YanYan Wei,1 YeGang Hu,1 HuiRu Cui,1 HuiJun Li,2 YingYing Tang,1 Li Hui,3 XiaoHua Liu,1 ChunBo Li,1 JiJun Wang,1,4,5 TianHong Zhang1 1Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laborat...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/afbae09b9d26423ba25d94701b731b9b |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:afbae09b9d26423ba25d94701b731b9b |
|---|---|
| record_format |
dspace |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
clinical high-risk early interventions antipsychotics subgroup Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
clinical high-risk early interventions antipsychotics subgroup Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Wu G Gan R Li Z Xu L Tang X Wei Y Hu Y Cui H Li H Tang Y Hui L Liu X Li C Wang J Zhang T Real-World Effectiveness and Safety of Antipsychotics in Individuals at Clinical High-Risk for Psychosis: Study Protocol for a Prospective Observational Study (ShangHai at Risk for Psychosis-Phase 2) |
| description |
GuiSen Wu,1 RanPiao Gan,1 ZhiXing Li,1 LiHua Xu,1 XiaoChen Tang,1 YanYan Wei,1 YeGang Hu,1 HuiRu Cui,1 HuiJun Li,2 YingYing Tang,1 Li Hui,3 XiaoHua Liu,1 ChunBo Li,1 JiJun Wang,1,4,5 TianHong Zhang1 1Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai 200030, People’s Republic of China; 2Florida a & M University, Department of Psychology, Tallahassee, FL 32307, USA; 3Institute of Mental Health, The Affiliated Guangji Hospital of Soochow University, Soochow University, Suzhou 215137, Jiangsu, People’s Republic of China; 4Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai, People’s Republic of China; 5Brain Science and Technology Research Center, Shanghai Jiao Tong University, Shanghai, People’s Republic of ChinaCorrespondence: TianHong Zhang; JiJun WangShanghai Key Laboratory of Psychotic Disorders (No.13dz2260500), Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, 600 Wanping Nan Road, Shanghai 200030, People’s Republic of ChinaTel +86-21-34773065Fax +86-21-64387986Email jijunwang27@163.comBackground: The clinical high-risk (CHR) state is identified as a critical period for early prevention and intervention during the development of psychosis and early treatment may reduce the risk of conversion to psychosis. However, it remains controversial whether antipsychotics are effective in CHR populations. Limited previous randomised controlled trials of antipsychotic treatment of CHR individuals indicated possible short-term efficacy on psychotic symptoms with unclear long-term effects. To answer this question, it is necessary to establish a high-quality real-world cohort study with large sample size to explore the effectiveness and safety of antipsychotics in CHR individuals.Methods: We plan to consecutively recruit 600 CHR individuals from Shanghai Mental Health Centre in the ongoing SHARP-2 (ShangHai At Risk for Psychosis-Phase 2) project between 2019 and 2022. At baseline, participants will be assessed by the Structured Interview for Prodromal Syndromes, the MATRICS Consensus Cognitive Battery, demographic information, and clinical medication history. They will be followed up in a naturalistic way in which the research team will not prescribe antipsychotics or provide pharmacological consultation. First, CHR participants and their families will be trained to record their medication daily and self-evaluate symptoms through smart-phone application-based assessment and report their information weekly. Second, telephone calls will be arranged monthly so that the researchers are informed about the participants’ symptoms, medications and daily functions. Third, face-to-face interviews will be conducted annually for repeating assessment of baseline. The primary outcomes will include conversion to psychosis and functional outcome (scored with less than 60 in the Global Assessment of Function) at the end of the follow-up period.Conclusion: The current study will improve our knowledge on the effectiveness and safety of the use of antipsychotics at the prodromal phase, and will eventually facilitate optimisation of individualised interventions for psychosis prevention and treatment.Keywords: clinical high-risk, early interventions, antipsychotics, subgroup |
| format |
article |
| author |
Wu G Gan R Li Z Xu L Tang X Wei Y Hu Y Cui H Li H Tang Y Hui L Liu X Li C Wang J Zhang T |
| author_facet |
Wu G Gan R Li Z Xu L Tang X Wei Y Hu Y Cui H Li H Tang Y Hui L Liu X Li C Wang J Zhang T |
| author_sort |
Wu G |
| title |
Real-World Effectiveness and Safety of Antipsychotics in Individuals at Clinical High-Risk for Psychosis: Study Protocol for a Prospective Observational Study (ShangHai at Risk for Psychosis-Phase 2) |
| title_short |
Real-World Effectiveness and Safety of Antipsychotics in Individuals at Clinical High-Risk for Psychosis: Study Protocol for a Prospective Observational Study (ShangHai at Risk for Psychosis-Phase 2) |
| title_full |
Real-World Effectiveness and Safety of Antipsychotics in Individuals at Clinical High-Risk for Psychosis: Study Protocol for a Prospective Observational Study (ShangHai at Risk for Psychosis-Phase 2) |
| title_fullStr |
Real-World Effectiveness and Safety of Antipsychotics in Individuals at Clinical High-Risk for Psychosis: Study Protocol for a Prospective Observational Study (ShangHai at Risk for Psychosis-Phase 2) |
| title_full_unstemmed |
Real-World Effectiveness and Safety of Antipsychotics in Individuals at Clinical High-Risk for Psychosis: Study Protocol for a Prospective Observational Study (ShangHai at Risk for Psychosis-Phase 2) |
| title_sort |
real-world effectiveness and safety of antipsychotics in individuals at clinical high-risk for psychosis: study protocol for a prospective observational study (shanghai at risk for psychosis-phase 2) |
| publisher |
Dove Medical Press |
| publishDate |
2019 |
| url |
https://doaj.org/article/afbae09b9d26423ba25d94701b731b9b |
| work_keys_str_mv |
AT wug realworldeffectivenessandsafetyofantipsychoticsinindividualsatclinicalhighriskforpsychosisstudyprotocolforaprospectiveobservationalstudyshanghaiatriskforpsychosisphase2 AT ganr realworldeffectivenessandsafetyofantipsychoticsinindividualsatclinicalhighriskforpsychosisstudyprotocolforaprospectiveobservationalstudyshanghaiatriskforpsychosisphase2 AT liz realworldeffectivenessandsafetyofantipsychoticsinindividualsatclinicalhighriskforpsychosisstudyprotocolforaprospectiveobservationalstudyshanghaiatriskforpsychosisphase2 AT xul realworldeffectivenessandsafetyofantipsychoticsinindividualsatclinicalhighriskforpsychosisstudyprotocolforaprospectiveobservationalstudyshanghaiatriskforpsychosisphase2 AT tangx realworldeffectivenessandsafetyofantipsychoticsinindividualsatclinicalhighriskforpsychosisstudyprotocolforaprospectiveobservationalstudyshanghaiatriskforpsychosisphase2 AT weiy realworldeffectivenessandsafetyofantipsychoticsinindividualsatclinicalhighriskforpsychosisstudyprotocolforaprospectiveobservationalstudyshanghaiatriskforpsychosisphase2 AT huy realworldeffectivenessandsafetyofantipsychoticsinindividualsatclinicalhighriskforpsychosisstudyprotocolforaprospectiveobservationalstudyshanghaiatriskforpsychosisphase2 AT cuih realworldeffectivenessandsafetyofantipsychoticsinindividualsatclinicalhighriskforpsychosisstudyprotocolforaprospectiveobservationalstudyshanghaiatriskforpsychosisphase2 AT lih realworldeffectivenessandsafetyofantipsychoticsinindividualsatclinicalhighriskforpsychosisstudyprotocolforaprospectiveobservationalstudyshanghaiatriskforpsychosisphase2 AT tangy realworldeffectivenessandsafetyofantipsychoticsinindividualsatclinicalhighriskforpsychosisstudyprotocolforaprospectiveobservationalstudyshanghaiatriskforpsychosisphase2 AT huil realworldeffectivenessandsafetyofantipsychoticsinindividualsatclinicalhighriskforpsychosisstudyprotocolforaprospectiveobservationalstudyshanghaiatriskforpsychosisphase2 AT liux realworldeffectivenessandsafetyofantipsychoticsinindividualsatclinicalhighriskforpsychosisstudyprotocolforaprospectiveobservationalstudyshanghaiatriskforpsychosisphase2 AT lic realworldeffectivenessandsafetyofantipsychoticsinindividualsatclinicalhighriskforpsychosisstudyprotocolforaprospectiveobservationalstudyshanghaiatriskforpsychosisphase2 AT wangj realworldeffectivenessandsafetyofantipsychoticsinindividualsatclinicalhighriskforpsychosisstudyprotocolforaprospectiveobservationalstudyshanghaiatriskforpsychosisphase2 AT zhangt realworldeffectivenessandsafetyofantipsychoticsinindividualsatclinicalhighriskforpsychosisstudyprotocolforaprospectiveobservationalstudyshanghaiatriskforpsychosisphase2 |
| _version_ |
1718400130096300032 |
| spelling |
oai:doaj.org-article:afbae09b9d26423ba25d94701b731b9b2021-12-02T06:02:57ZReal-World Effectiveness and Safety of Antipsychotics in Individuals at Clinical High-Risk for Psychosis: Study Protocol for a Prospective Observational Study (ShangHai at Risk for Psychosis-Phase 2)1178-2021https://doaj.org/article/afbae09b9d26423ba25d94701b731b9b2019-12-01T00:00:00Zhttps://www.dovepress.com/real-world-effectiveness-and-safety-of-antipsychotics-in-individuals-a-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021GuiSen Wu,1 RanPiao Gan,1 ZhiXing Li,1 LiHua Xu,1 XiaoChen Tang,1 YanYan Wei,1 YeGang Hu,1 HuiRu Cui,1 HuiJun Li,2 YingYing Tang,1 Li Hui,3 XiaoHua Liu,1 ChunBo Li,1 JiJun Wang,1,4,5 TianHong Zhang1 1Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai 200030, People’s Republic of China; 2Florida a & M University, Department of Psychology, Tallahassee, FL 32307, USA; 3Institute of Mental Health, The Affiliated Guangji Hospital of Soochow University, Soochow University, Suzhou 215137, Jiangsu, People’s Republic of China; 4Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai, People’s Republic of China; 5Brain Science and Technology Research Center, Shanghai Jiao Tong University, Shanghai, People’s Republic of ChinaCorrespondence: TianHong Zhang; JiJun WangShanghai Key Laboratory of Psychotic Disorders (No.13dz2260500), Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, 600 Wanping Nan Road, Shanghai 200030, People’s Republic of ChinaTel +86-21-34773065Fax +86-21-64387986Email jijunwang27@163.comBackground: The clinical high-risk (CHR) state is identified as a critical period for early prevention and intervention during the development of psychosis and early treatment may reduce the risk of conversion to psychosis. However, it remains controversial whether antipsychotics are effective in CHR populations. Limited previous randomised controlled trials of antipsychotic treatment of CHR individuals indicated possible short-term efficacy on psychotic symptoms with unclear long-term effects. To answer this question, it is necessary to establish a high-quality real-world cohort study with large sample size to explore the effectiveness and safety of antipsychotics in CHR individuals.Methods: We plan to consecutively recruit 600 CHR individuals from Shanghai Mental Health Centre in the ongoing SHARP-2 (ShangHai At Risk for Psychosis-Phase 2) project between 2019 and 2022. At baseline, participants will be assessed by the Structured Interview for Prodromal Syndromes, the MATRICS Consensus Cognitive Battery, demographic information, and clinical medication history. They will be followed up in a naturalistic way in which the research team will not prescribe antipsychotics or provide pharmacological consultation. First, CHR participants and their families will be trained to record their medication daily and self-evaluate symptoms through smart-phone application-based assessment and report their information weekly. Second, telephone calls will be arranged monthly so that the researchers are informed about the participants’ symptoms, medications and daily functions. Third, face-to-face interviews will be conducted annually for repeating assessment of baseline. The primary outcomes will include conversion to psychosis and functional outcome (scored with less than 60 in the Global Assessment of Function) at the end of the follow-up period.Conclusion: The current study will improve our knowledge on the effectiveness and safety of the use of antipsychotics at the prodromal phase, and will eventually facilitate optimisation of individualised interventions for psychosis prevention and treatment.Keywords: clinical high-risk, early interventions, antipsychotics, subgroupWu GGan RLi ZXu LTang XWei YHu YCui HLi HTang YHui LLiu XLi CWang JZhang TDove Medical Pressarticleclinical high-riskearly interventionsantipsychoticssubgroupNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 15, Pp 3541-3548 (2019) |